Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2000-02-22
2001-10-16
Whisenant, Ethan (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C536S023100, C536S024300
Reexamination Certificate
active
06303314
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the field of treatment of autoimmune disease, such as multiple sclerosis (MS). More particularly, it concerns a T-cell receptor sequence found in some MS patients, and methods for its detection.
2. Description of Related Art
In humans and other mammals, T cell receptors are found on T cells. T cell receptors comprise &agr; and &bgr; chains, with &bgr; chains comprising the following regions from N-terminus to C-terminus: V&bgr;-D&bgr;-J&bgr;-C&bgr;. T cell receptors naturally vary in the V&bgr;-D&bgr;-J&bgr; regions.
When an antigen is presented to the T cells by an antigen-presenting cell (APC), a T cell receptor with variable regions (including V&bgr;-D&bgr;-J&bgr;) that so happen to recognize the antigen binds to the antigen on the APC. The T cell bearing the T cell receptor then undergoes activation (clonal expansion).
The pathogenesis of a number of autoimmune diseases is believed to lie in autoimmune T cell responses to antigens presented normally by the organism. An example of such a disease is multiple sclerosis (MS), which is generally held to arise in T cell responses to myelin antigens, in particular myelin basic protein (MBP). MBP-reactive T cells are found to undergo in vivo activation, and occur at a higher precursor frequency in blood and cerebrospinal fluid in patients with MS as opposed to control individuals. These MBP-reactive T cells produce Th1 cytokines, e.g. IL-2, TNF, and &ggr;-interferon. These Th1 cytokines facilitate migration of inflammatory cells into the central nervous system and exacerbate myelin-destructive inflammatory responses in MS.
A number of regulatory mechanisms can be made use of in the treatment of MS. One such is vaccination with one or more of the limited number of T cell membrane-associated peptides with extracellular domains. Vandenbark, U.S. Pat. No. 5,614,192, discloses treatment of autoimmune diseases by the use of immunogenic T cell receptor peptides of 15 to 30 amino acids comprising at least part of the second complementarity determining region (CDR2) of the T cell receptor. A copending U.S. patent application by Zhang (No. 60/099,102) discloses treatment of autoimmune diseases by use of immunogenic T cell receptor peptides in combination with immunogenic T cell activation marker peptides.
One area in which vaccination with T cell receptor peptides can be improved is by determining which, if any, common motifs are found in the T cell receptors of a patient with an autoimmune disease such as MS. If such motifs are found, then the patient can be vaccinated with peptides identical to the motifs, in order to facilitate treatment.
Therefore, it is desirable to have the amino acid sequences of common motifs found in the T cell receptors of patients with autoimmune diseases. It is also desirable to be able to readily detect such motifs in a patient sample by a convenient method, such as PCR. In addition, it is desirable to use peptides identical to the detected motifs to treat a patient with the autoimmune disease.
The present invention discloses such a common motif found in the T cell receptors of a subset of V&bgr;13.1 T cells, the “LGRAGLTY motif”, which has the amino acid sequence Lue Gly Arg Ala Gly Leu Thr Tyr (SEQ ID NO: 3), as well as a method for its ready detection by PCR. This motif is found in some T cell receptors of some T cells that recognize amino acids 83-99 of MBP (hereinafter “MBP83-99”). The motif in the context of this subset of V&bgr;13.1 T cells may hereinafter be referred to as “V&bgr;13.1-LGRAGLTY.” Peptides identical to the motif can be used to vaccinate patients in order to treat or prevent autoimmune diseases with which V&bgr;13.1-LGRAGLTY is associated. One such autoimmune disease is MS.
SUMMARY OF THE INVENTION
In one embodiment, the present invention is directed to an oligonucleotide from about 15 to 30 nucleotides in length which comprises at least 10 contiguous nucleotides of SEQ ID NO:1, or a sequence complementary thereto or derived therefrom. Even more preferable is an oligonucleotide, of about 15 to 30 nucleotides in length, which comprises 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of SEQ ID NO:, or a sequence complementary thereto. Most preferable is an oligonucleotide, of about 15 to 30 nucleotides in length, which comprises the nucleotide sequence of SEQ ID NO:1, or the sequence complementary thereto.
In a series of further embodiments, the oligonucleotide can be used in amplification or detection of a nucleic acid sequence found in V&bgr;13.1-LGRAGLTY T cells. In one subseries of such embodiments, the oligonucleotide is used in a primer pair, the primer pair comprising or derived from:
(a) a first primer which is an oligonucleotide is from about 15 to 30 nucleotides in length and comprises at least 10 contiguous nucleotides of SEQ ID NO:1, or a sequence complementary thereto; and
(b) a second primer which is an oligonucleotide of about 15 and 30 nucleotides in length that does not comprise the sequence (a), and said second primer sequence can be found in the region from V&bgr; to J&bgr; of the V&bgr;13.1 gene (SEQ ID NO: 2) in T cell receptor T cells,
wherein the sequences of (a) and (b) are not found on the same strand of the T cell receptor gene.
Preferably said first primer is an oligonucleotide, of about 15 to 30 nucleotides in length, which comprises 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of SEQ ID NO:1, or a sequence complementary thereto. Most preferable is an oligonucleotide, of about 15 to 30 nucleotides in length, which comprises the nucleotide sequence of SEQ ID NO:1, or the sequence complementary thereto.
In another subseries of such embodiments, the oligonucleotide is used as an oligonucleotide probe, the oligonucleotide probe comprising:
(a) an oligonucleotide from about 15 to 30 nucleotides in length and comprises at least 10 contiguous nucleotides of SEQ ID NO:1, or a sequence complementary thereto; and
(b) a labeling moiety.
Preferably, the oligonucleotide, is about 15 to 30 nucleotides in length, and comprises 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of SEQ ID NO:1, or a sequence complementary thereto. Most preferable is an oligonucleotide, of about 15 to 30 nucleotides in length, which comprises the nucleotide sequence of SEQ ID NO:1, or the sequence complementary thereto. The labeling moiety is preferably selected from
32
P or digoxingenin.
In another embodiment, the present invention is directed to a method of detecting MBP83-99 V&bgr;13.1 T cells expressing a LGRAGLTY motif, comprising:
(i) obtaining a nucleic acid sample from MBP83-99 V&bgr;13.1 T cells;
(ii) contacting the nucleic acid sample with a primer pair selected or derived from:
(a) a first primer comprising an oligonucleotide of about 15 to 30 nucleotides in length and comprises at least 10 contiguous nucleotides of SEQ ID NO:1, or a sequence complementary thereto or derived therefrom; and
(b) a second primer comprising and oligonucleotide of about 15 and 30 nucleotides in length that does not comprise the sequence of (a) and is found in the region from V&bgr; to J&bgr; of the V&bgr;13.1 gene in V&bgr;13.1 T cells (SEQ ID NO:2),
wherein the sequences of (a) and (b) are not found on the same strand of the V&bgr;13.1 gene; and,
(iii) detecting the presence of the nucleic acid encoding the LGRAGLTY motif.
Preferably the first primer is an oligonucleotide, of about 15 to 30 nucleotides in length, which comprises 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleotides of SEQ ID NO:, or a sequence complementary thereto. Most preferable is an oligonucleotide, of about 15 to 30 nucleotides in length, which comprises the nucleotide sequence of SEQ ID NO:1, or the sequence complementary thereto.
In yet another embodiment, the present invention is directed to a method of treating an autoimmune disease, comprising:
(a) obtaining MBP83-99 V&bgr;13.1 T cells from a human;
(b) detecting the presence
Baylor College of Medicine
Howrey Simon Arnold & White , LLP
Whisenant Ethan
LandOfFree
T-cell receptor V&bgr;-D&bgr;-J&bgr; sequence and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with T-cell receptor V&bgr;-D&bgr;-J&bgr; sequence and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and T-cell receptor V&bgr;-D&bgr;-J&bgr; sequence and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2608335